OncoTherapy Science Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2016 - 2020
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	2016 - 2020
Net Income	-813	-1,285	-1,116	-2,570	-1,560	Upgrade
Depreciation & Amortization	-	-	-	16	49	Upgrade
Loss (Gain) From Sale of Assets	-	154	21	547	10	Upgrade
Other Operating Activities	-2	-2	-17	-3	-3	Upgrade
Change in Accounts Receivable	-63	87	276	-247	-123	Upgrade
Change in Inventory	-4	25	131	-189	-16	Upgrade
Change in Accounts Payable	21	-158	-240	385	-39	Upgrade
Change in Other Net Operating Assets	46	-48	151	-12	-80	Upgrade
Operating Cash Flow	-815	-1,227	-794	-2,073	-1,762	Upgrade
Capital Expenditures	-	-2	-4	-456	-43	Upgrade
Other Investing Activities	-	-31	-16	-11	-9	Upgrade
Investing Cash Flow	-	-33	-20	-467	-52	Upgrade
Issuance of Common Stock	1,178	676	-	1,478	-	Upgrade
Repurchase of Common Stock	-1	-	-	-	-	Upgrade
Other Financing Activities	-56	-5	95	-	-	Upgrade
Financing Cash Flow	1,121	671	95	1,478	-	Upgrade
Net Cash Flow	306	-589	-719	-1,062	-1,814	Upgrade
Free Cash Flow	-815	-1,229	-798	-2,529	-1,805	Upgrade
Free Cash Flow Margin	-108.67%	-201.47%	-70.37%	-219.34%	-543.67%	Upgrade
Free Cash Flow Per Share	-3.12	-5.78	-4.14	-13.49	-10.24	Upgrade
Cash Interest Paid	1	-	-	-	-	Upgrade
Cash Income Tax Paid	2	2	2	2	2	Upgrade
Levered Free Cash Flow	-512.75	-937	-231.88	-1,782	-1,196	Upgrade
Unlevered Free Cash Flow	-512.13	-937	-231.88	-1,782	-1,196	Upgrade
Change in Net Working Capital	14	235	-464	59	178	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.